High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

Cancer

Volumn 79, Issue 6, 1997, Pages 1129-1137

  Gutman, Mordechai ^a   Inbar, Moshe ^a   Lev Shlush, Dina ^a   Abu Abid, Subhi ^a   Mozes, Martha ^a   Chaitchik, Samario ^a   Meller, Itzhak ^a   Klausner, Joseph M ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

isolated limb perfusion; limb sparing surgery; melphalan; soft tissue sarcoma; tumor necrosis factor

Indexed keywords

DOXORUBICIN; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; LEUKOPENIA; LIMB AMPUTATION; LIMB PERFUSION; MALE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEG; MALE; MELPHALAN; MIDDLE AGED; SARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030889278     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970315)79:6<1129::AID-CNCR11>3.0.CO;2-1     Document Type: Article

References (38)

1. Haranaka K, Satomi N, Sukari A. Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984;34:263-7.
2. Asher AL, Mule JY, Reichert CM, Shiloni E, Rosenberg SA. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
3. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039-44.
4. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987;5:1942-51.
5. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman J. A phase I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients. J Clin Oncol 1988;6:1328-34.
6. Tracey KJ, Beutler B, Lowry SF, Merryweather S, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-3.
7. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
8. Rosenberg SA, Suit HD, Barker LH. Sarcomas of soft tissue. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Philadelphia: J.B. Lippincott, 1993:1436-88.
9. Schraffordt-Koops H, Kroon BBR, Lejeune FJ. Isolated regional perfusion in the treatment of local recurrence, satellites and in transit metastases of extremity melanoma. In: Rumke P, editor. Therapy of advanced malignant melanoma. Volume 10. Pigment cell series. Basel:Karger Press, 1990:67-78.
10. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs in regional perfusion. Ann Surg 1977;185:555-63.
11. McBride CM. Sarcomas of the limbs: results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974; 109:304-8.
12. Hoekstra HS, Schraffordt-Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of soft tissue tumors of the extremities. Cancer 1987;60:1703-7.
13. Eggermont AMM, Schraffordt-Koops H, Kroon B, Klausner JM, Schlag PM, Lejeune FJ. The European experience in TNFα isolated limb perfusions for nonresectable extremity soft tissue sarcomas; 85% response rate; 87% limb salvage. [abstract 217]. Proceedings of the European Conference on Clinical Oncology (ECCO 8) Meeting; October 29-November 2, 1995, Paris.
14. Fraker DL, Alexander HR. Isolated limb perfusion with high dose tumor necrosis factor for extremity melanoma and sarcoma. In: De Vita VT Jr., Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: J.B. Lippincott Co., 1994:179-92.
15. Schraffordt-Koops H, Eggermont AMM, Lienard D, Soni N, Williams T, Thomas JM. Isolated limb perfusion (ILP) with high dose TNF-alpha, gamma-IFN and melphalan in patients with irresectable soft tissue sarcomas: a highly effective limb saving procedure. Eur J Cancer 1993;29A(Suppl 6):1017-5183.
16. Inbar M, Abu-Abid S, Lev D, Chaitchik S, Klausner JM. r-Tumor necrosis factor alpha with melphalan administration via isolated limb perfusion (ILP) for extensive soft tissue sarcoma. Proc Am Soc Clin Oncol 1994;13:481, 1679.
17. Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon and melphalan. Cancer 1994; 73:483-92.
18. Enneking WF, Spanier SS, Goodman MA. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 1980;62:1027-30.
19. Krementz ET, Ryan RF, Muchmore JH, Carter RD, Sutherland CM, Reed RJ. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma. 2nd edition. Philadelphia: J.B. Lippincott Co., 1992:403-22.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Sorkin P, Abu-Abid S, Lev D, Gutman M, Aderka D, Halpern P, et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995;130:1079-84.
22. Weiberdink J, Benkhuijsen C, Brapd RP, Van-Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
23. Lawrence W, Donegan WL, Natrajan N, Metlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349-59.
24. Eilber FR, Eckhardt JF, Rosen G, Fu YS, Seeger LL, Selch MT. Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft tissue sarcomas of the extremity. Surg Oncol Clin North Am 1993;2:611-20.
25. Sugarman BJ, Aggarwal BB, Mass PF, Figari IS, Palladino MA Jr., Shepard HM. Recombinant tumor necrosis factor-α: effects of proliferation of normal and transformed cells in vitro. Science 1985;230:943-5.
26. Beutler B, Cerami A. Tumor necrosis, cachexia shock and inflammation: a common mediator. Ann Rev Biochem 1988; 57:505-18.
27. Quinn TD, Polk HC Jr., Edwards MJ. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines. Cancer Immunol Immunother 1995;40:272-5.
28. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, et al. Toxic effect of TNF on tumor vasculature in mice. Cancer Res 1988;49:2179-83.
29. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5.
30. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium. Characterization and comparison with actions of interleukin-I. Proc Natl Acad Sci USA 1986;83:4533-5437.
31. Cheresh DA. Integrin αVβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. 38th Annual Conference on Advances in the Biology and Clinical Management of Melanoma, Houston, Texas, February 21-24, 1995.
32. Regenass A, Muller M, Curschellas E, Matter A. Anti tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 1987;39:266-73.
33. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, et al. Tumor necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53:829-36.
34. Krosnick JA, Mule JJ, McIntosh JK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 1989;49:3729-33.
35. Watanabe N, Niitso Y, Umeno N, Sone H, Neda H, Yamauchi N, et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988;48:650-3.
36. Robbins HI, d'Oleire F, Kutz M, Bird A, Schmitt-Tiggler CL, Cohen JD, et al. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia. Cancer Lett 1995;89:55-62.
37. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kou GC, et al. Anti cachetin/TNF antibodies prevent septic shock lethal bacteremia. Nature 1987;330:662-4.
38. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high dose tumor necrosis factor, interferon gamma and melphalan. J Clin Oncol 1995;13:264-73.